CN104231019B - 单萜苷类化合物在制备抗补体药物中的用途 - Google Patents
单萜苷类化合物在制备抗补体药物中的用途 Download PDFInfo
- Publication number
- CN104231019B CN104231019B CN201310222868.1A CN201310222868A CN104231019B CN 104231019 B CN104231019 B CN 104231019B CN 201310222868 A CN201310222868 A CN 201310222868A CN 104231019 B CN104231019 B CN 104231019B
- Authority
- CN
- China
- Prior art keywords
- compound
- mudanpioside
- work
- nmr
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(c(cc1)ccc1O*=C)=O Chemical compound CC(c(cc1)ccc1O*=C)=O 0.000 description 2
- RDZIUEQEKIOZPR-UHFFFAOYSA-N CC(c(cc1OC)cc([O](C)=C)c1[O](=C)=N)=O Chemical compound CC(c(cc1OC)cc([O](C)=C)c1[O](=C)=N)=O RDZIUEQEKIOZPR-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明属中药制药领域,涉及单萜苷类化合物在制备抗补体药物中的新用途。本发明采应用现代药理研究方法,对芍药属植物牡丹(Paeonia suffruticosa Andr.)的干燥根皮抗补体活性物质进行研究,从其95%乙醇提取物的乙酸乙酯萃取部位和正丁醇部位分离得到8个单萜苷类化合物,并证实其对补体系统经典途径和旁路途径均有较强的抑制作用。所述化合物对补体系统经典途径的抑制作用(CH50)为0.09‑0.47 mg/ml,对旁路途径的抑制作用(AP50)为0.16‑0.63 mg/ml。所述化合物可用于制备补体抑制剂。
Description
技术领域
本发明属中药制药领域,涉及丹皮中单萜苷类化合物及其在制备抗补体药物中的新用途。
背景技术
补体系统的过度激活会引发系统性红斑狼疮、类风湿性关节炎、急性呼吸窘迫综合征等多种重大疾病。抗补体药物研究多年来一直是世界药学研究的热点和重点。然而目前对此类疾病尚缺乏较为理想的治疗药物,因此临床上急需高效、低毒、专一的新型补体抑制剂。从天然产物中研究开发补体抑制剂是近年来一个受到越来越多关注的重要研究领域,其具有成本低、毒性低等特点。国内外学者已从包括海洋生物在内的多种天然产物中分离得到多种具有补体系统抑制作用的单体化合物,为抗补体药物的研究与开发提供了广阔的前景。
丹皮为毛茛科芍药属植物牡丹(Paeonia suffruticosa Andr.)的干燥根皮,为一重要的常用中药,其性微寒,味苦,辛,具有清热凉血,活血化瘀的功效,用于吐血钮血、经闭痛经、痈肿疮毒等症。现代药理学研究表明丹皮中的单萜苷类化合物具有抗炎、抗变态、抗氧化、降血糖等多种活性,但尚未见其抗补体活性报道。
发明内容
本发明的目的是提供丹皮中新的具有抗补体活性的化合物,具体涉及丹皮中具有抗补体活性的化合物,其包括下述8个单萜苷类化合物:没食子酰芍药苷(galloylpaeoniflorin,1)、没食子酰氧化芍芍苷(galloyl-oxypaeoniflorin,2)、mudanpioside B(3)、mudanpioside C(4)、mudanpioside E(5)、mudanpioside H(6)、benzoyloxypaeoniflorin(7)、suffrupaeoniflorin A(8),其中化合物suffrupaeoniflorin A(8)为新化合物。
本发明的进一步目的是提供上述丹皮中单萜苷类化合物在制药中的新用途,尤其是在制备抗补体药物中的用途。
本发明应用现代药理研究方法,对从芍药属植物牡丹(Paeonia suffruticosaAndr.)的干燥根皮乙醇提取物的乙酸乙酯和正丁醇萃取部位中分离得到8个单萜苷类成分进行抗补体活性评价,结果证实,所述的化合物对补体系统经典途径和旁路途径均有较强的抑制作用,所述化合物对补体系统经典途径的抑制作用(CH50)为0.09-0.47mg/ml,对旁路途径的抑制作用(AP50)为0.16-0.63mg/ml。
本发明所述的单萜苷类化合物可用于制备补体抑制剂,进一步制备抗补体药物。
本发明的活性单萜苷类化合物具有以下结构通式的化学结构:
当R1=G,R2=R3=R4=H,化合物为没食子酰芍药苷(1);
当R1=G,R2=R4=H,R3=OH,化合物为没食子酰氧化芍药苷(2);
当R1=MBz,R2=R4=H,R3=OH,化合物为mudanpioside B(3);
当R1=HBz,R2=R3=R4=H,化合物为mudanpioside C(4);
当R1=R2=H,R3=OH,R4=OCH3,化合物为mudanpioside E(5);
当R1=HBz,R2=R4=H,R3=OH,化合物为mudanpioside H(6);
当R1=Bz,R2=R4=H,R3=OH,化合物为benzoyloxypaeoniflorin(7);
当R1=Bz,R2=glucose,R3=OH,R4=H,化合物为suffrupaeoniflorin A(8)。
本发明所述的单萜苷类化合物通过下述方法制备:
取丹皮20kg,粉碎,用95%乙醇室温冷浸(40L×3次),合并提取液并浓缩得2.6kg的浸膏,取其中的1.0kg浸膏加水混悬,依次以等体积乙酸乙酯、正丁醇萃取(各2.0L×5次),合并各萃取液并浓缩至干,得乙酸乙酯萃取物390g及正丁醇萃取物260g。取乙酸乙酯萃取部位经硅胶(200-300目)柱色谱分离,依次以二氯甲烷-甲醇(30:1-0:1)梯度洗脱,得到10个流份(Fr.1-10),其中流份Fr.4(30g)再经硅胶柱色谱(氯仿-甲醇为洗脱剂,30:1,20:1,15:1,10:1,3:1)和制备HPLC(甲醇:水,3:7)和Sephadex LH-20反复纯化,分离得到化合物没食子酰芍药苷(galloylpaeoniflorin,1)、mudanpioside B(3)、mudanpioside C(4)、mudanpioside H(6)、benzoyloxypaeoniflorin(7);取正丁醇部位浸膏加水混悬,上样于Diaion HP-20树脂,依次用水,25%、50%、75%、100%甲醇水溶液洗脱,得5个流份(PS-BU-1~5)。流份(PS-BU-3~4)分别经ODS柱色谱(甲醇:水,25:75-100:0)和Sephadex LH-20反复纯化,得化合物没食子酰氧化芍芍苷(galloyloxypaeoniflorin,2)、mudanpioside E(5)、suffrupaeoniflorin A(8)。
化合物1没食子酰芍药苷(galloylpaeoniflorin):淡黄色固体;分子式:C30H32O15;分子量:632;1H-NMR(400MHz,CD3OD)δ:8.03(2H,d,J=7.4Hz,H-2',6'),7.60(1H,t,J=7.4Hz,H-4'),7.47(2H,d,J=7.4Hz,H-3',5'),7.07(2H,s,H-2”,6”),5.38(1H,s,H-9),4.69(2H,s,H-8),4.54(1H,d,J=7.4Hz,H-1”'),4.46(2H,m,H-6”'),3.52(1H,t,J=7.0Hz,H-5”'),3.36(1H,m,H-4”'),3.34(1H,m,H-3”'),3.24(1H,t,J=7.5Hz,H-2”'),2.53(1H,d,J=6.2Hz,H-5),2.45(1H,dd,J=10.5,7.0Hz,H-6),1.91(1H,d,J=13.0Hz,H-3),1.74(1H,d,J=10.5Hz,H-6),1.70(1H,d,J=13.0Hz,H-3),1.25(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:168.1(C-7”),168.0(C-7'),146.6(C-3”,5”),139.9(C-4”),134.4(C-4'),131.2(C-1'),130.7(C-2',6'),129.6(C-3',5'),121.3(C-1”),110.1(C-2”,6”),106.3(C-4),102.2(C-9),99.9(C-1”'),89.3(C-1),87.2(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.0(C-7),71.9(C-4”'),64.7(C-6”'),61.6(C-8),44.4(C-3),43.7(C-5),22.9(C-6),19.6(C-10)。
化合物2没食子酰氧化芍药苷(galloyloxypaeoniflorin):淡黄色固体;分子式:C30H32O16;分子量:648;1H-NMR(400MHz,400MHz,CD3OD)δ:7.89(2H,d,J=8.6Hz,H-2',6'),7.07(2H,s,H-2”,6”),6.82(2H,d,J=8.6Hz,H-3',5'),5.36(1H,s,H-9),4.64(2H,s,H-8),4.53(1H,d,J=7.8Hz,H-1”'),4.47(1H,d,J=12.0Hz,H-6”'),4.43(1H,dd,J=12.0,7.0Hz,H-6”'),3.54(1H,t,J=7.0Hz,H-5”'),3.32(1H,m,H-4”'),3.30(1H,m,H-3”'),3.24(1H,t,J=7.5Hz,H-2”'),2.51(1H,d,J=6.2Hz,H-5),2.44(1H,d,J=10.5Hz,H-6),1.91(1H,d,J=12.5Hz,H-3),1.72(1H,d,J=10.5Hz,H-6),1.68(1H,d,J=12.5Hz,H-3),1.25(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:168.1(C-7”),168.0(C-7'),163.7(C-4'),146.6(C-3”,5”),139.9(C-4”),132.9(C-2',6'),121,9(C-1'),121.4(C-1”),116.2(C-3',5'),110.1(C-2”,6”),106.3(C-4),102.2(C-9),99.9(C-1”'),89.3(C-1),87.2(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.0(C-7),71.9(C-4”'),64.7(C-6”'),61.1(C-8),44.4(C-3),43.7(C-5),22.9(C-6),19.6(C-10)。
化合物3mudanpioside B:白色固体,分子式:C31H34O14;分子量:630;1H-NMR(400MHz,Acetone-d6)δ:8.00(2H,d,J=9.0Hz,H-2”,6”),7.91(2H,d,J=8.6Hz,H-2',6'),7.02(2H,d,J=8.6Hz,Hz,H-3',5'),6.92(2H,d,J=9.0Hz,H-3”,5”),5.32(1H,s,H-9),4.64(2H,m,H-8),4.62(2H,m,H-6”'),4.43(1H,d,J=7.4Hz,H-1”'),3.87(3H,s,OCH3-4”),3.65(1H,t,J=7.0Hz,H-5”'),3.42(1H,m,H-4”'),3.39(1H,m,H-3”'),3.29(1H,m,H-2”'),2.49(2H,d,J=6.2Hz,H-5,6),1.90(1H,d,J=12.0Hz,H-3),1.76(1H,dd,J=10.0,5.0Hz,H-6),1.67(1H,d,J=12.0Hz,H-3),1.23(3H,s,CH3-10);13C-NMR(100MHz,Acetone-d6)δ:166.6(C-7'),166.2(C-7”),164.5(C-4”),162.7(C-4'),132.6(C-2',6'),132.2C-2”,6”),123.3(C-1”),122.2(C-1'),116.0(C-3',5'),114.6(C-3”,5”),105.5(C-4),101.5(C-9),99.6(C-1”'),88.9(C-1),85.9(C-2),77.8(C-3”'),74.8(C-5”'),74.7(C-2”'),71.6(C-4”'),71.4(C-7),64.6(C-6”'),60.6(C-8),55.9(OCH3-4”)44.4(C-3),43.6(C-5),22.8(C-6),19.6(C-10)。
化合物4mudanpioside C:白色固体,分子式:C30H32O13;分子量:600;1H-NMR(400MHz,CD3OD)δ:8.02(2H,d,J=7.4Hz,H-2',6'),7.89(2H,d,J=8.6Hz,H-2”,6”),7.60(1H,t,J=7.4,Hz,H-5'),7.50(2H,d,J=7.4Hz,H-3',5'),6.82(2H,d,J=8.6Hz,H-3”,5”),5.38(1H,s,H-9),4.70(2H,s,H-8),4.58(1H,dd,J=11.3,7.0Hz,H-6”'),4.56(1H,d,J=7.4Hz,H-1”'),4.43(1H,dd,J=11.3,7.0Hz,H-6”'),3.56(1H,t,J=7.0Hz,H-5”'),3.35(1H,m,H-4”'),3.34(1H,m,H-3”'),3.24(1H,t,J=8.2Hz,H-2”'),2.52(1H,d,J=6.2Hz,H-5),2.47(1H,d,J=10.5Hz,H-6),1.87(1H,d,J=12.5Hz,H-3),1.72(1H,d,J=10.5Hz,H-6),1.70(1H,d,J=12.5Hz,H-3),1.25(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7”),167.7(C-7'),163.7(C-4”),134.4(C-4'),132.8(C-2”,6”),131.2(C-1'),130.7(C-2',6'),129.6(C-3',5'),122.0(C-1”),116.3(C-3”,5”),106.2(C-4),102.2(C-9),99.9(C-1”'),89.2(C-1),87.1(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.1(C-7),71.9(C-4”'),64.7(C-6”'),61.6(C-8),44.4(C-3),43.7(C-5),22.9(C-6),19.6(C-10)。
化合物5mudanpioside E:白色固体,分子式:C24H30O13;分子量:526;1H-NMR(400MHz,CD3OD)δ:7.58(1H,dd,J=8.2,2.0Hz,H-6'),7.55(1H,d,J=2.0Hz,H-2'),6.85(1H,d,J=8.2,Hz,H-5'),5.41(1H,s,H-9),4.72(2H,d,J=16.8,Hz,H-8),4.67(1H,d,J=11.3Hz,H-6”),4.52(1H,d,J=7.4Hz,H-1”),3.89(3H,s,OCH3-3'),3.85(1H,d,J=11.3Hz,H-6”),3.59(1H,m,H-5”),3.32(1H,m,H-4”),3.30(1H,m,H-3”),3.21(1H,m,H-2”),2.57(1H,d,J=7.6Hz,H-5),2.47(1H,dd,J=11.0,7.0Hz,H-6),2.19(1H,d,J=12.5Hz,H-3),1.95(1H,d,J=11.0Hz,H-6),1.80(1H,d,J=12.5Hz,H-3),1.36(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7'),152.9(C-4'),148.8(C-3'),125.2(C-6'),122.3(C-1'),115.9(C-5'),113.6.0(C-2'),106.4(C-4),102.3(C-9),100.2(C-1”'),89.3(C-1),87.2(C-2),78.0(C-3”),77.9(C-5”),74.9(C-2”),72.3(C-7),71.7(C-4”),62.3(C-6”),61.3(C-8),56.5(OCH3-3'),44.5(C-3),43.9(C-5),23.4(C-6),19.6(C-10)。
化合物6mudanpiosideH:白色固体;分子式:C30H32O14;分子量:616;1H-NMR(400MHz,CD3OD)δ:7.89(4H,d,J=8.6Hz,H-2',6',2”,6”),6.82(4H,d,J=8.6Hz,H-3',5',3',5'),5.36(1H,s,H-9),4.64(2H,s,H-8),4.55(1H,d,J=7.4Hz,H-1”'),4.58(1H,m,H-6”'),4.44(1H,m,H-6”'),3.56(1H,t,J=7.8Hz,H-5”'),3.37(1H,m,H-4”'),3.34(1H,m,H-3”'),3.24(1H,t,J=7.8Hz,H-2”'),2.48(1H,m,H-5),2.45(1H,m,H-6),1.87(1H,d,J=12.5Hz,H-3),1.69(1H,m,H-6),1.67(1H,m,H-3),1.24(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:168.0(C-7”),167.7(C-7'),163.7(C-4”),163.7(C-4'),132.9(C-2”,6”),132.8(C-2',6'),122.0(C-1”),121.9(C-1'),116.3(C-3”,5”),116.2(C-3',5'),106.2(C-4),102.2(C-9),99.9(C-1”'),89.2(C-1),87.0(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.1(C-7),72.1(C-4”'),64.7(C-6”'),61.1(C-8),44.4(C-3),43.7(C-5),23.0(C-6),19.6(C-10)。
化合物7benzoyloxypaeoniflorin:白色固体,分子式:C30H32O13;分子量:600;1H-NMR(400MHz,CD3OD)δ:8.03(2H,d,J=7.4Hz,H-2”,6”),7.89(2H,d,J=8.6Hz,H-2',6'),7.60(1H,t,J=7.4Hz,Hz,H-4”),7.47(2H,t,J=7.4Hz,H-3”,5”),6.82(2H,d,J=8.6Hz,H-3',5'),5.36(1H,s,H-9),4.64(2H,s,H-8),4.62(1H,d,J=2Hz,H-6”'),4.56(1H,d,J=7.8Hz,H-1”'),4.49(1H,dd,J=11.7,7.0Hz,H-6”'),3.59(1H,t,J=7.0Hz,H-5”'),3.36(1H,m,H-4”'),3.35(1H,m,H-3”'),3.25(1H,t,J=8.2Hz,H-2”'),2.47(1H,d,J=6.0Hz,H-5),2.43(1H,d,J=11.0Hz,H-6),1.83(1H,d,J=12.5Hz,H-3),1.67(1H,d,J=11.0Hz,H-6),1.66(1H,d,J=12.5Hz,H-3),1.23(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7'),167.6(C-7”),163.7(C-4'),134.5(C-4”),132.9(C-2',6'),131.3(C-1”),130.6(C-2”,6”),129.7(C-3”,5”),121.9(C-1'),116.2(C-3',5'),106.2(C-4),102.2(C-9),99.9(C-1”'),89.2(C-1),87.1(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.0(C-7),72.0(C-4”'),65.1(C-6”'),61.1(C-8),44.4(C-3),43.7(C-5),23.0(C-6),19.6(C-10)。
化合物8suffrupaeoniflorin A:淡黄色固体,分子式:C36H42O18;分子量:762;1H-NMR(400MHz,CD3OD)δ:8.04(2H,d,J=7.4Hz,H-2”,6”),7.89(2H,d,J=8.6Hz,H-2',6'),7.61(1H,d,J=7.4Hz,Hz,H-4”),7.48(2H,d,J=7.4Hz,H-3”,5”),6.82(2H,d,J=8.6Hz,H-3',5'),5.36(1H,s,H-9),4.83(1H,d,J=11.3Hz,H-6”'),4.64(2H,s,H-8),4.60(1H,d,J=11.3Hz,H-6”'),4.59(1H,d,J=7.8Hz,H-1”'),4.40(1H,d,J=7.8Hz,H-1””),3.75(1H,m,H-5”'),3.57(1H,m,H-4”'),3.53(1H,m,H-3”'),3.29(1H,m,H-2”'),3.87(2H,m,H-6””),3.34(1H,m,H-5””),3.28(1H,m,H-4””),3.33(1H,m,H-3””),3.25(1H,m,H-2””),2.49(1H,d,J=6.3Hz,H-5),2.47(1H,d,J=10.5Hz,H-6),1.83(1H,d,J=12.5Hz,H-3),1.69(1H,d,J=10.5Hz,H-6),1.66(1H,d,J=12.5Hz,H-3),1.20(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7'),167.5(C-7”),163.7(C-4'),134.5(C-4”),133.0(C-2',6'),131.3(C-1”),130.6(C-2”,6”),129.7(C-3”,5”),122.0(C-1'),116.2(C-3',5'),106.2 104.8(C-1””),(C-4),102.2(C-9),99.8(C-1”'),89.3(C-1),87.0(C-2),81.3(C-4”'),78.3(C-5””),77.8(C-3””),76.3(C-3”'),75.2(C-5”'),74.9(C-2””),74.6(C-2”'),73.9(C-5”'),72.0(C-7),71.4(C-4””),64.6(C-6”'),62.5(C-6””),61.1(C-8),44.4(C-3),43.8(C-5),23.0(C-6),19.5(C-10)。
上述单萜苷类化合物经过体外抗补体活性试验测定,结果表明上述单萜苷类化合物对补体系统的经典途径和旁路途径均有较强的抑制作用,50%溶血所需最小供试品浓度分别为0.09-0.47mg/ml,0.16-0.63mg/m(如表1所示)。
表1.化合物1-8对补体系统经典途径和旁路途径的抑制作用(Mean±SD,n=3)
附图说明:
图1.丹皮中单萜苷类化合物1-8的提取分离流程图。
为了便于理解,以下将通过具体的附图和实施例对本发明进行详细地描述。需要特别指出的是,具体实例和附图仅是为了说明,显然本领域的普通技术人员可以根据本文说明,在本发明的范围内对本发明做出各种各样的修正和改变,这些修正和改变也纳入本发明的范围内。
具体实施方式
实施例1.制备单萜苷类化合物
取丹皮20kg,粉碎,用95%乙醇室温冷浸(40L×3次),合并提取液并浓缩得2.6kg的浸膏,取其中的1.0kg浸膏加水混悬,依次以等体积乙酸乙酯、正丁醇萃取(各2.0L×5次),合并各萃取液并浓缩至干,得乙酸乙酯萃取物390g及正丁醇萃取物260g。取乙酸乙酯萃取部位经硅胶(200-300目)柱色谱分离,依次以二氯甲烷-甲醇(30:1-0:1)梯度洗脱,得到10个流份(Fr.1-10),其中流份Fr.4(30g)再经硅胶柱色谱(氯仿-甲醇为洗脱剂,30:1,20:1,15:1,10:1,3:1)和制备HPLC(甲醇:水,3:7)和Sephadex LH-20反复纯化,分离得到化合物没食子酰芍药苷(galloylpaeoniflorin,1)、mudanpioside B(3)、mudanpioside C(4)、mudanpioside H(6)、benzoyloxypaeoniflorin(7);取正丁醇部位浸膏加水混悬,上样于Diaion HP-20树脂,依次用水,25%、50%、75%、100%甲醇水溶液洗脱,得5个流份(PS-BU-1~5)。流份(PS-BU-3~4)分别经ODS柱色谱(甲醇:水,25:75-100:0)和Sephadex LH-20反复纯化,得化合物没食子酰氧化芍芍苷(galloyloxypaeoniflorin,2)、mudanpioside E(5)、suffrupaeoniflorin A(8)。
化合物1没食子酰芍药苷(galloylpaeoniflorin):淡黄色固体;分子式:C30H32O15;分子量:632;1H-NMR(400MHz,CD3OD)δ:8.03(2H,d,J=7.4Hz,H-2',6'),7.60(1H,t,J=7.4Hz,H-4'),7.47(2H,d,J=7.4Hz,H-3',5'),7.07(2H,s,H-2”,6”),5.38(1H,s,H-9),4.69(2H,s,H-8),4.54(1H,d,J=7.4Hz,H-1”'),4.46(2H,m,H-6”'),3.52(1H,t,J=7.0Hz,H-5”'),3.36(1H,m,H-4”'),3.34(1H,m,H-3”'),3.24(1H,t,J=7.5Hz,H-2”'),2.53(1H,d,J=6.2Hz,H-5),2.45(1H,dd,J=10.5,7.0Hz,H-6),1.91(1H,d,J=13.0Hz,H-3),1.74(1H,d,J=10.5Hz,H-6),1.70(1H,d,J=13.0Hz,H-3),1.25(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:168.1(C-7”),168.0(C-7'),146.6(C-3”,5”),139.9(C-4”),134.4(C-4'),131.2(C-1'),130.7(C-2',6'),129.6(C-3',5'),121.3(C-1”),110.1(C-2”,6”),106.3(C-4),102.2(C-9),99.9(C-1”'),89.3(C-1),87.2(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.0(C-7),71.9(C-4”'),64.7(C-6”'),61.6(C-8),44.4(C-3),43.7(C-5),22.9(C-6),19.6(C-10)。
化合物2没食子酰氧化芍药苷(galloyloxypaeoniflorin):淡黄色固体;分子式:C30H32O16;分子量:648;1H-NMR(400MHz,400MHz,CD3OD)δ:7.89(2H,d,J=8.6Hz,H-2',6'),7.07(2H,s,H-2”,6”),6.82(2H,d,J=8.6Hz,H-3',5'),5.36(1H,s,H-9),4.64(2H,s,H-8),4.53(1H,d,J=7.8Hz,H-1”'),4.47(1H,d,J=12.0Hz,H-6”'),4.43(1H,dd,J=12.0,7.0Hz,H-6”'),3.54(1H,t,J=7.0Hz,H-5”'),3.32(1H,m,H-4”'),3.30(1H,m,H-3”'),3.24(1H,t,J=7.5Hz,H-2”'),2.51(1H,d,J=6.2Hz,H-5),2.44(1H,d,J=10.5Hz,H-6),1.91(1H,d,J=12.5Hz,H-3),1.72(1H,d,J=10.5Hz,H-6),1.68(1H,d,J=12.5Hz,H-3),1.25(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:168.1(C-7”),168.0(C-7'),163.7(C-4'),146.6(C-3”,5”),139.9(C-4”),132.9(C-2',6'),121,9(C-1'),121.4(C-1”),116.2(C-3',5'),110.1(C-2”,6”),106.3(C-4),102.2(C-9),99.9(C-1”'),89.3(C-1),87.2(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.0(C-7),71.9(C-4”'),64.7(C-6”'),61.1(C-8),44.4(C-3),43.7(C-5),22.9(C-6),19.6(C-10)。
化合物3mudanpioside B:白色固体,分子式:C31H34O14;分子量:630;1H-NMR(400MHz,Acetone-d6)δ:8.00(2H,d,J=9.0Hz,H-2”,6”),7.91(2H,d,J=8.6Hz,H-2',6'),7.02(2H,d,J=8.6Hz,Hz,H-3',5'),6.92(2H,d,J=9.0Hz,H-3”,5”),5.32(1H,s,H-9),4.64(2H,m,H-8),4.62(2H,m,H-6”'),4.43(1H,d,J=7.4Hz,H-1”'),3.87(3H,s,OCH3-4”),3.65(1H,t,J=7.0Hz,H-5”'),3.42(1H,m,H-4”'),3.39(1H,m,H-3”'),3.29(1H,m,H-2”'),2.49(2H,d,J=6.2Hz,H-5,6),1.90(1H,d,J=12.0Hz,H-3),1.76(1H,dd,J=10.0,5.0Hz,H-6),1.67(1H,d,J=12.0Hz,H-3),1.23(3H,s,CH3-10);13C-NMR(100MHz,Acetone-d6)δ:166.6(C-7'),166.2(C-7”),164.5(C-4”),162.7(C-4'),132.6(C-2',6'),132.2C-2”,6”),123.3(C-1”),122.2(C-1'),116.0(C-3',5'),114.6(C-3”,5”),105.5(C-4),101.5(C-9),99.6(C-1”'),88.9(C-1),85.9(C-2),77.8(C-3”'),74.8(C-5”'),74.7(C-2”'),71.6(C-4”'),71.4(C-7),64.6(C-6”'),60.6(C-8),55.9(OCH3-4”)44.4(C-3),43.6(C-5),22.8(C-6),19.6(C-10)。
化合物4mudanpioside C:白色固体,分子式:C30H32O13;分子量:600;1H-NMR(400MHz,CD3OD)δ:8.02(2H,d,J=7.4Hz,H-2',6'),7.89(2H,d,J=8.6Hz,H-2”,6”),7.60(1H,t,J=7.4,Hz,H-5'),7.50(2H,d,J=7.4Hz,H-3',5'),6.82(2H,d,J=8.6Hz,H-3”,5”),5.38(1H,s,H-9),4.70(2H,s,H-8),4.58(1H,dd,J=11.3,7.0Hz,H-6”'),4.56(1H,d,J=7.4Hz,H-1”'),4.43(1H,dd,J=11.3,7.0Hz,H-6”'),3.56(1H,t,J=7.0Hz,H-5”'),3.35(1H,m,H-4”'),3.34(1H,m,H-3”'),3.24(1H,t,J=8.2Hz,H-2”'),2.52(1H,d,J=6.2Hz,H-5),2.47(1H,d,J=10.5Hz,H-6),1.87(1H,d,J=12.5Hz,H-3),1.72(1H,d,J=10.5Hz,H-6),1.70(1H,d,J=12.5Hz,H-3),1.25(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7”),167.7(C-7'),163.7(C-4”),134.4(C-4'),132.8(C-2”,6”),131.2(C-1'),130.7(C-2',6'),129.6(C-3',5'),122.0(C-1”),116.3(C-3”,5”),106.2(C-4),102.2(C-9),99.9(C-1”'),89.2(C-1),87.1(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.1(C-7),71.9(C-4”'),64.7(C-6”'),61.6(C-8),44.4(C-3),43.7(C-5),22.9(C-6),19.6(C-10)。
化合物5mudanpioside E:白色固体,分子式:C24H30O13;分子量:526;1H-NMR(400MHz,CD3OD)δ:7.58(1H,dd,J=8.2,2.0Hz,H-6'),7.55(1H,d,J=2.0Hz,H-2'),6.85(1H,d,J=8.2,Hz,H-5'),5.41(1H,s,H-9),4.72(2H,d,J=16.8,Hz,H-8),4.67(1H,d,J=11.3Hz,H-6”),4.52(1H,d,J=7.4Hz,H-1”),3.89(3H,s,OCH3-3'),3.85(1H,d,J=11.3Hz,H-6”),3.59(1H,m,H-5”),3.32(1H,m,H-4”),3.30(1H,m,H-3”),3.21(1H,m,H-2”),2.57(1H,d,J=7.6Hz,H-5),2.47(1H,dd,J=11.0,7.0Hz,H-6),2.19(1H,d,J=12.5Hz,H-3),1.95(1H,d,J=11.0Hz,H-6),1.80(1H,d,J=12.5Hz,H-3),1.36(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7'),152.9(C-4'),148.8(C-3'),125.2(C-6'),122.3(C-1'),115.9(C-5'),113.6.0(C-2'),106.4(C-4),102.3(C-9),100.2(C-1”'),89.3(C-1),87.2(C-2),78.0(C-3”),77.9(C-5”),74.9(C-2”),72.3(C-7),71.7(C-4”),62.3(C-6”),61.3(C-8),56.5(OCH3-3'),44.5(C-3),43.9(C-5),23.4(C-6),19.6(C-10)。
化合物6mudanpiosideH:白色固体;分子式:C30H32O14;分子量:616;1H-NMR(400MHz,CD3OD)δ:7.89(4H,d,J=8.6Hz,H-2',6',2”,6”),6.82(4H,d,J=8.6Hz,H-3',5',3',5'),5.36(1H,s,H-9),4.64(2H,s,H-8),4.55(1H,d,J=7.4Hz,H-1”'),4.58(1H,m,H-6”'),4.44(1H,m,H-6”'),3.56(1H,t,J=7.8Hz,H-5”'),3.37(1H,m,H-4”'),3.34(1H,m,H-3”'),3.24(1H,t,J=7.8Hz,H-2”'),2.48(1H,m,H-5),2.45(1H,m,H-6),1.87(1H,d,J=12.5Hz,H-3),1.69(1H,m,H-6),1.67(1H,m,H-3),1.24(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:168.0(C-7”),167.7(C-7'),163.7(C-4”),163.7(C-4'),132.9(C-2”,6”),132.8(C-2',6'),122.0(C-1”),121.9(C-1'),116.3(C-3”,5”),116.2(C-3',5'),106.2(C-4),102.2(C-9),99.9(C-1”'),89.2(C-1),87.0(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.1(C-7),72.1(C-4”'),64.7(C-6”'),61.1(C-8),44.4(C-3),43.7(C-5),23.0(C-6),19.6(C-10)。
化合物7benzoyloxypaeoniflorin:白色固体,分子式:C30H32O13;分子量:600;1H-NMR(400MHz,CD3OD)δ:8.03(2H,d,J=7.4Hz,H-2”,6”),7.89(2H,d,J=8.6Hz,H-2',6'),7.60(1H,t,J=7.4Hz,Hz,H-4”),7.47(2H,t,J=7.4Hz,H-3”,5”),6.82(2H,d,J=8.6Hz,H-3',5'),5.36(1H,s,H-9),4.64(2H,s,H-8),4.62(1H,d,J=2Hz,H-6”'),4.56(1H,d,J=7.8Hz,H-1”'),4.49(1H,dd,J=11.7,7.0Hz,H-6”'),3.59(1H,t,J=7.0Hz,H-5”'),3.36(1H,m,H-4”'),3.35(1H,m,H-3”'),3.25(1H,t,J=8.2Hz,H-2”'),2.47(1H,d,J=6.0Hz,H-5),2.43(1H,d,J=11.0Hz,H-6),1.83(1H,d,J=12.5Hz,H-3),1.67(1H,d,J=11.0Hz,H-6),1.66(1H,d,J=12.5Hz,H-3),1.23(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7'),167.6(C-7”),163.7(C-4'),134.5(C-4”),132.9(C-2',6'),131.3(C-1”),130.6(C-2”,6”),129.7(C-3”,5”),121.9(C-1'),116.2(C-3',5'),106.2(C-4),102.2(C-9),99.9(C-1”'),89.2(C-1),87.1(C-2),77.8(C-3”'),75.2(C-5”'),74.9(C-2”'),72.0(C-7),72.0(C-4”'),65.1(C-6”'),61.1(C-8),44.4(C-3),43.7(C-5),23.0(C-6),19.6(C-10)。
化合物8suffrupaeoniflorin A:淡黄色固体,分子式:C36H42O18;分子量:762;1H-NMR(400MHz,CD3OD)δ:8.04(2H,d,J=7.4Hz,H-2”,6”),7.89(2H,d,J=8.6Hz,H-2',6'),7.61(1H,d,J=7.4Hz,Hz,H-4”),7.48(2H,d,J=7.4Hz,H-3”,5”),6.82(2H,d,J=8.6Hz,H-3',5'),5.36(1H,s,H-9),4.83(1H,d,J=11.3Hz,H-6”'),4.64(2H,s,H-8),4.60(1H,d,J=11.3Hz,H-6”'),4.59(1H,d,J=7.8Hz,H-1”'),4.40(1H,d,J=7.8Hz,H-1””),3.75(1H,m,H-5”'),3.57(1H,m,H-4”'),3.53(1H,m,H-3”'),3.29(1H,m,H-2”'),3.87(2H,m,H-6””),3.34(1H,m,H-5””),3.28(1H,m,H-4””),3.33(1H,m,H-3””),3.25(1H,m,H-2””),2.49(1H,d,J=6.3Hz,H-5),2.47(1H,d,J=10.5Hz,H-6),1.83(1H,d,J=12.5Hz,H-3),1.69(1H,d,J=10.5Hz,H-6),1.66(1H,d,J=12.5Hz,H-3),1.20(3H,s,CH3-10);13C-NMR(100MHz,CD3OD)δ:167.9(C-7'),167.5(C-7”),163.7(C-4'),134.5(C-4”),133.0(C-2',6'),131.3(C-1”),130.6(C-2”,6”),129.7(C-3”,5”),122.0(C-1'),116.2(C-3',5'),106.2 104.8(C-1””),(C-4),102.2(C-9),99.8(C-1”'),89.3(C-1),87.0(C-2),81.3(C-4”'),78.3(C-5””),77.8(C-3””),76.3(C-3”'),75.2(C-5”'),74.9(C-2””),74.6(C-2”'),73.9(C-5”'),72.0(C-7),71.4(C-4””),64.6(C-6”'),62.5(C-6””),61.1(C-8),44.4(C-3),43.8(C-5),23.0(C-6),19.5(C-10)。
上述单萜苷类化合物经过体外抗补体活性试验测定,结果表明上述单萜苷类化合物对补体系统的经典途径和旁路途径均有较强的抑制作用,50%溶血所需最小供试品浓度分别为0.09-0.47mg/ml,0.16-0.63mg/m(如表1所示)。
实施例2.体外抗补体经典途径试验
取补体(豚鼠血清)0.1ml,加入巴比妥缓冲液(BBS)配制成1:10的溶液,用BBS对倍稀释成1:20、1:40、1:80、1:160、1:320、1:640和1:1280的溶液。取1:1000溶血素、各浓度补体及2%羊红细胞(SRBC)各0.1ml溶于0.3ml BBS中,混匀,37℃水浴30min后放入低温高速离心机,在5000rpm、4℃条件下离心10min。分别取每管上清0.2ml于96孔板,在405nm测定其吸光度。实验同时设置全溶血组(0.1ml 2%SRBC溶于0.5ml三蒸水)。以三蒸水溶血管的吸光度作为全溶血标准,计算溶血率。以补体稀释度为X轴,溶血百分率为Y轴作图。选择达到相似高溶血率的最低补体浓度作为确保体系能正常溶血所需的临界补体浓度。取临界浓度的补体与供试品混匀,加入适量BBS、溶血素和2%SRBC,37℃水浴30min后放入低温高速离心机,5000rpm、4℃条件下离心10min后分别取每管上清0.2ml于96孔板,405nm下测定吸光度。实验同时设置供试品对照组、补体组和全溶血组。将供试品吸光度值扣除相应供试品对照组吸光度值后计算溶血率。以供试品浓度作为X轴,溶血抑制率作为Y轴作图,计算50%抑制溶血所需供试品的浓度(CH50)。
实施例3.体外抗补体旁路途径试验
取补体(人血清)0.2ml,加入AP稀释液(巴比妥缓冲液,pH=7.4,含5mM Mg2+,8mMEGTA)配制成1:5的溶液,并对倍稀释成1:10、1:20、1:40、1:80、1:160、1:320和1:640的溶液。取各浓度补体0.15ml、AP稀释液0.15ml及0.5%兔红细胞(RE)0.20ml,混匀,37℃水浴30min后置于低温高速离心机,在5000rpm、4℃条件下离心10min。分别取每管上清0.2ml于96孔板,在405nm测定吸光度。实验同时设置全溶血组(0.20ml 0.5%RE溶于0.3ml三蒸水)。以三蒸水溶血管的吸光度作为全溶血标准,计算溶血率。以补体稀释度为X轴,溶血百分率为Y轴作图。选择达到相似高溶血率的最低补体浓度作为确保体系能正常溶血所需的临界补体浓度。取确定的临界浓度的补体与供试品混匀,于37℃预水浴10min后,加入0.2ml0.5%RE。将每管37℃水浴30min后置于低温高速离心机,5000rpm、4℃条件下离心10min后,分别取每管上清0.2ml于96孔板,405nm下测定其吸光度。实验同时设置供试品对照组、补体组和全溶血组。将供试品吸光度值扣除相应供试品对照组吸光度值后计算溶血率。以供试品浓度作为X轴,溶血抑制率作为Y轴作图,计算50%抑制溶血所需供试品的浓度(AP50)
经过体外抗补体活性试验测定,结果表明本发明的单萜苷类化合物对补体系统的经典途径和旁路途径均有较强的抑制作用,50%溶血所需最小供试品浓度分别为0.09-0.47mg/ml,0.16-0.63mg/m(如表1所示)。
表1.化合物1-8对补体系统经典途径和旁路途径的抑制作用(Mean±SD,n=3)
本发明中实验采用的试剂均为本领域公知技术,可市购。
Claims (4)
1.具有以下结构通式的单萜苷类化合物在制备抗补体药物中的用途:
当R1=G,R2=R3=R4=H,化合物为没食子酰芍药苷;
当R1=G,R2=R4=H,R3=OH,化合物为没食子酰氧化芍药苷;
当R1=MBz,R2=R4=H,R3=OH,化合物为mudanpioside B;
当R1=HBz,R2=R3=R4=H,化合物为mudanpioside C;
当R1=R2=H,R3=OH,R4=OCH3,化合物为mudanpioside E;
当R1=HBz,R2=R4=H,R3=OH,化合物为mudanpioside H;
当R1=Bz,R2=R4=H,R3=OH,化合物为benzoyloxypaeoniflorin;
当R1=Bz,R2=glucose,R3=OH,R4=H,化合物为suffrupaeoniflorin A。
2.按权利要求1所述的用途,其特征在于,所述的单萜苷类化合物通过下述方法制备:
取丹皮,粉碎,用95%乙醇室温冷浸,提取液减压回收溶剂得浸膏,取其中的浸膏加水混悬,依次以乙酸乙酯、正丁醇萃取,合并各萃取液并浓缩至干,得乙酸乙酯萃取物及正丁醇萃取物;取乙酸乙酯萃取部位经硅胶柱色谱分离,以二氯甲烷-甲醇梯度洗脱,所得流份经硅胶柱色谱、制备HPLC和Sephadex LH-20反复纯化,分离得到化合物没食子酰芍药苷、mudanpioside B、mudanpioside C、mudanpioside H、benzoyloxypaeoniflorin;取正丁醇部位浸膏加水混悬,上样于Diaion HP-20树脂,依次用水,25%,50%,75%,100%甲醇水溶液洗脱,所得流份经ODS柱色谱和Sephadex LH-20反复纯化,得化合物没食子酰氧化芍芍苷、mudanpioside E、suffrupaeoniflorin A。
3.按权利要求1所述的用途,其特征在于,所述的单萜苷类化合物对补体系统经典途径和旁路途径有抑制作用。
4.按权利要求3所述的用途,其特征在于,所述的单萜苷类化合物对补体系统经典途径的抑制作用CH50为0.09-0.47mg/ml,对旁路途径的抑制作用AP50为0.16-0.63mg/ml。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310222868.1A CN104231019B (zh) | 2013-06-06 | 2013-06-06 | 单萜苷类化合物在制备抗补体药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310222868.1A CN104231019B (zh) | 2013-06-06 | 2013-06-06 | 单萜苷类化合物在制备抗补体药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104231019A CN104231019A (zh) | 2014-12-24 |
CN104231019B true CN104231019B (zh) | 2017-05-10 |
Family
ID=52220009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310222868.1A Expired - Fee Related CN104231019B (zh) | 2013-06-06 | 2013-06-06 | 单萜苷类化合物在制备抗补体药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104231019B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108191931B (zh) * | 2018-01-24 | 2021-08-10 | 中国药科大学 | 新疆芍药中的三种新化合物及其保健和医药用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903259A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种丹皮药材的提取分离方法 |
WO2007106049A1 (en) * | 2006-03-16 | 2007-09-20 | Moleac Pte Ltd | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
CN101181373A (zh) * | 2007-12-07 | 2008-05-21 | 戴敏 | 丹皮有效部位药物组合物、其制备方法及应用 |
-
2013
- 2013-06-06 CN CN201310222868.1A patent/CN104231019B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903259A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种丹皮药材的提取分离方法 |
WO2007106049A1 (en) * | 2006-03-16 | 2007-09-20 | Moleac Pte Ltd | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
CN101181373A (zh) * | 2007-12-07 | 2008-05-21 | 戴敏 | 丹皮有效部位药物组合物、其制备方法及应用 |
Non-Patent Citations (5)
Title |
---|
Bioactive Constituents of Chinese Natural Medicines. VI.1) Moutan Cortex. (2): Structures and Radical Scavenging Effects of Suffruticosides A, B, C, D, and E and Galloyl-oxypaeoniflorin;Hisashi MATSUDA,等;《Chem. Pharm. Bull.》;20010131;第49卷(第1期);69-72 * |
Characterization of compounds in the Chinese herbal drug Mu-Dan-Pi by liquid chromatography coupled to electrospray ionization mass spectrometry;Shun-jun Xu,等;《RAPID COMMUNICATIONS IN MASS SPECTROMETRY》;20061017;第20卷(第22期);3275–3288 * |
GALLOYL-OXYPAEONIFLORIN, SUFFRUTICOSIDES A,B,C,AND D, FIVE NEW ANTIOXIDATIVE GLYCOSIDES, AND SUFFRUTICOSIDE E, A PAEONOL GLYCOSIDE, FROM CHINESE MOUTAN CORTEX;Masayuki Yoshikawa,等;《Chem. Pharm. Bull.》;19921231;第40卷(第8期);2248-2250 * |
Identification of multiple constituents in the traditional Chinese medicine formula GuiZhiFuLing-Wan by HPLC-DAD-MS/MS;Lu Chen,等;《Journal of Pharmaceutical and Biomedical Analysis》;20081119;第49卷(第2期);267–275 * |
丹皮的抗炎作用;巫冠中,等;《中国药科大学学报》;19901231;第21卷(第4期);222-225 * |
Also Published As
Publication number | Publication date |
---|---|
CN104231019A (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103508919B (zh) | 生物碱类化合物及其在制备抗补体药物中的用途 | |
CN103508922A (zh) | 二肽类化合物及其在制备抗补体药物中的用途 | |
CN102432620B (zh) | 一种白藜芦醇四聚体化合物及其制备方法和应用 | |
CN104231019B (zh) | 单萜苷类化合物在制备抗补体药物中的用途 | |
CN106619652A (zh) | 阔叶丰花草三萜化合物的制备方法及其在制备糖苷酶抑制剂药物中的应用 | |
CN101766664B (zh) | 一种岗梅总皂苷提取物的检测方法 | |
CN103565928A (zh) | 一种番石榴降糖活性组分、制备方法及用途 | |
CN109810154B (zh) | 小花清风藤生物碱类化合物、制备方法、应用及其组合物 | |
CN105194079A (zh) | 黑果枸杞果实提取物在制药中的应用 | |
CN105078965B (zh) | 吉马烷内酯倍半萜类化合物在制备抗补体药物中的用途 | |
CN104231012B (zh) | 酚苷类化合物及其在制备抗补体药物中的用途 | |
CN105985403B (zh) | 一种甾醇内酯及其在制备抗补体药物中的用途 | |
CN105985347B (zh) | 一种苯并大环内酰胺吲哚生物碱及其在制备抗补体药物中的用途 | |
CN105777686A (zh) | 酒石酸麦角胺的药物组合物及其在生物医药中的应用 | |
CN106606506A (zh) | 对映半日花烷型二萜在制备抗补体药物中的用途 | |
CN105520926A (zh) | 木脂素类化合物(7s,8r)-二氢脱氢二松柏醇在制备抗补体药物中的用途 | |
CN108164574B (zh) | 小花清风藤中的一种化合物及其制备方法与应用 | |
CN105777683A (zh) | 双环醇的药物组合物及其医药用途 | |
KR20110087395A (ko) | 푸슈로틴 디를 유효성분으로 함유하는 암 질환의 예방 및 치료용 조성물 | |
CN102100721A (zh) | 一种亳菊总黄酮的生产方法 | |
CN112851612A (zh) | 一种从牛蒡叶中提取的具有降低胆固醇活性化合物及其制备方法与应用 | |
CN105859547A (zh) | 厄贝沙坦的药物组合物及其在生物医药中的应用 | |
CN107550899B (zh) | 环烯醚萜类化合物轮叶马先蒿素a或轮叶马先蒿素b在制备抗补体药物中的用途 | |
CN105078937B (zh) | 双环吉马烷型倍半萜类化合物在制备抗补体药物中的用途 | |
CN105837592A (zh) | 间苯三酚骈松香烷二萜类化合物及其制备方法和药物用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170510 Termination date: 20200606 |
|
CF01 | Termination of patent right due to non-payment of annual fee |